New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback